Please select
your location below

Attenzione, le pagine di questa sezione sono disponibili solo in lingua inglese.

By selecting the International view, you verify that you reside outside of the USA and you wish to view DiaSorin Molecular’s International Product Information. This material is intended for International (non-USA) site visitors only.

Pursuant to the Guidelines of the Ministry of Health dated 28/03/2013 related to health advertising concerning medical devices, in vitro diagnostic medical devices and medical-surgical devices, we hereby inform you that the information contained in this website and to which you are going to access is exclusively intended for professionaloperators.

xTAG^® CYP2C19 Kit v3

Help clinicians identify mutations indicative of adverse effects with certain drugs

xTAG 2C19 is a highly scalable genetics test with clinically relevant mutations.

Disease state

Cytochrome P450 2C19 (CYP2C19) metabolize 5% of the prescription drugs in use today. Genotypic variants of CYP2C19 change how these drugs are metabolized. CYP2C19*2 and CYP2C19*3 variants account for approximately 99% of Asian and 87% of Caucasians poor metabolizers, respectively. Over one-third of Caucasians and over 40% of patients of African and Asian ancestry harbor gain-of-function and loss-of-function 2C19 variants. These variants are linked to a higher risk of adverse events with certain drugs.

CYP2C19 mutations are potential indicators of poor drug metabolism

The value of xTAG^® CYP2C19 Kit v3

Empower clinicians to accurately identify clinically relevant CYP2C19 mutations: CYP2C19*2, CYP2C19*3, and CYP2C19*17.

Reliable

Detect and identify clinically relevant genotypes.

Resource efficient

Obtain flexibility in throughput with Luminex^® 200™ platform and MAGPIX^® instrument.

Actionable

Gain confidence in results with high accuracy and reproducibility.

How the xTAG^® CYP2C19 Kit v3 test works

xTAG^® CYP2C19 Kit v3 is a multiplexed nucleic acid test intended for the detection of clinically relevant mutations *2, *3, *17.

High complexity workflow

Nucleic acid extraction and purification, multiplex amplification, bead hybridization and detection, and data acquisition and analysis by MAGPIX^® or Luminex^® 200™ with xPONENT^®software.

Time to results

Within 8 hours, a laboratory can detect and determine the relevant genotypes for their clients.

Indications for xTAG^® CYP2C19 Kit v3 Test use

Assay and system

A multiplexed nucleic acid test for the detection of 2C19 from EDTA and Citrate Blood.